Product Usage: This product is intended for research purposes only.
All product information available on this website is for educational purposes only. Any form of bodily introduction into humans or animals is strictly prohibited by law. This product should only be handled by licensed and qualified professionals. It is not a drug, food, or cosmetic, and must not be misbranded, misused, or mislabeled as such.
Sunifiram – powder, 10 grams
During our packaging transition, you may receive products with either our previous or updated label. Rest assured, the formulation, purity and quality remain exactly same as standards.
Sunifiram (DM-235) is a synthetic pyrrolidinone-derived compound structurally distinct from the classical racetam family despite sharing a related core scaffold, investigated for proposed positive allosteric modulation of AMPA-type glutamate receptors. Research interest centers on its reported high in vitro potency relative to piracetam-class compounds at substantially lower concentrations. Research applications include AMPA receptor potentiator pharmacology, glutamatergic signalling research, and structure-activity comparison within the pyrrolidinone-derivative compound series.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
3D Molecular Structure
Drag to rotate · scroll to zoom| Chemical Formula | C14H18N2O2 |
|---|---|
| Synonyms | DM-235 |
| Molar Mass | 246.304 g/mol |
| CAS Number | 314728-85-3 |
| PubChem CID | 4223812 |
| Total Compound Content | 10 grams |
| Shelf Life | 36 months |
Every batch is independently lab tested for identity, purity and potency. View our lab testing program →
How does sunifiram's structure relate to and differ from the classical racetam compound family?
Sunifiram shares a pyrrolidinone-derived structural lineage conceptually related to the racetam family but is synthesized via a distinct chemical route and carries substituents not present in piracetam, oxiracetam, or other classical racetam-family compounds. This structural distinction is the basis for research comparing sunifiram's receptor-binding and functional potency profile against established racetam compounds, particularly given reports of substantially different potency ranges between the two groups in similar assay systems.
What electrophysiological methods characterize sunifiram's proposed AMPA receptor potentiating activity?
Patch-clamp electrophysiology in cultured neurons, brain slice preparations, or heterologous expression systems is the standard method for characterising sunifiram's effects on AMPA receptor-mediated currents, with key readouts including peak current amplitude, desensitization rate, and deactivation kinetics in the presence versus absence of the compound. These functional measurements are used alongside receptor-binding assays to determine whether sunifiram acts at an allosteric site distinct from the glutamate orthosteric binding site, consistent with a positive allosteric modulator mechanism.
What concentration ranges are typically used in research characterizing sunifiram's in vitro potency?
Reports of sunifiram's in vitro activity describe substantially lower effective concentrations than those required for classical racetam-family compounds in comparable assay systems, prompting researchers to use nanomolar-to-low-micromolar concentration ranges when establishing dose-response curves for sunifiram, in contrast to the micromolar-to-millimolar ranges typically required for piracetam-class compounds. Researchers should empirically establish the relevant concentration range for their specific assay system and cell model rather than assuming direct potency transfer from other reported studies.
-
SALE
-
-
-
